Dual Agonist
A single molecule that activates two hormone receptors — tirzepatide's GLP-1 + GIP design.
A dual agonist is one engineered molecule carrying two keys: tirzepatide activates both the GLP-1 receptor (appetite, gastric emptying, insulin) and the GIP receptor (insulin response, fat-tissue energy handling). The design bet was that two complementary signals would outperform a stronger dose of one — and SURMOUNT-1's 22.5% average at the top dose made the case.
Dual agonism is also why cross-drug comparisons need care: tirzepatide isn't "stronger semaglutide," it's a different mechanism profile, with its own side-effect texture and its own responders. Some patients do better on one than the other, which keeps individualized prescribing — not leaderboard-reading — at the center of good treatment.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Dual Agonist? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment